Table 5.
Cell Line/Animal Model | Treatment | Effects | Reference | |
---|---|---|---|---|
OVCAR-3 | 0–25 µM TF3 24 h |
↓ Cell viability ↓ Angiogenesis ↓ VEGF ↓ HIF-1a ↓ p-Akt |
↓ p-mTOR, ↓ p-p70s6k ↓ p-4E-BP1 ↓ c-Myc ↓ NOTCH-1 cleavage |
[43] |
OVCAR-3, A2780/CP70 | 0–40 µM TF1, TF2a, TF2b, and TF3 24 h |
↓ Proliferation ↑ Apoptosis ↓ Angiogenesis ↓ VEGF secretion ↓ HIF-1a ↑ Caspases-3, -7, -8, and -9 activity |
↑ Bax ↑ FADD ↑ DR5 ↓ Bcl-xL ↓ HIF-1a |
[44] |
A2780/CP70 | TF3 | ↑ Cytotoxicity ↓ Cell viability ↑ Apoptosis ↑ Caspases-3, -7 activity ↑ Cell cycle arrest at the G2 phase ↑ Bax ↑ Bad ↑ Cleaved caspase-9 ↑ Cleaved caspase-8 |
↑ DR5 ↑ FADD ↓ Bcl-xL ↓ Procaspase-8 ↓ Procaspase-9 ↓ Cyclin B1 ↓ MDM2 ↑ p-Akt ↑ p-53 |
[45] |
A2780/CP70 | 0–40 µM TF-2a 24 h |
↓ Proliferation ↓ Cell viability ↑ LDH ↑ Early phase apoptosis ↑ Late phase apoptosis ↑ Caspase -3, -7 activity ↓ Pro-caspase-3, -7 ↑ Cleaved caspase-3, -7 ↑ Full length PARP ↑ Cleaved PARP ↑ G1 phase ↓ S phase ↓ G2 phase ↓ CDK2 |
↓ CDK4 ↑ p21 ↑ p53 ↑ p-histone H2A.X ↑ p-ATM ↑ ATM ↑ p-Chk1 (Ser345) ↑ p-Chk2 (Thr68) ↑ p-p53 (Ser15) ↓ Akt ↑ p-p38 ↓ ERK1/2 ↓ JNK2 |
[46] |
A2780/CP70, OVCAR-3 | 2.5–22.5 µM TF3 24 h |
↓ Cell viability ↓ GSH↑ CTR1 |
[47] | |
A2780/CP70, OVCAR-3 |
5–20 µM TF3 24 h |
↓ Cell viability ↓ Cell colonies ↓ Proliferation ↑ %ALDH+ cells ↑ Apoptosis |
↑ Caspase-3, -7 ↓ β-catenin ↓LEF-1 ↓c-Myc ↓Cyclin D1 |
[48] |
A2780/CP70, OVCAR-3 | 5–50 µM TF3 24 h 7.0 µM TF3 24 h |
↓ Cell viability ↓ Cell colonies ↑ Apoptosis |
↑ G1 phase arrest ↓ G2 phase cells ↓ Cyclin D1↓ CDK4 |
[49] |
OVCAR-3 |
0–30 μM TF3 24 h |
↑ Apoptosis ↓ Cell viability ↑ Cleaved PARP ↑ Bax ↑ Cleaved caspases-3, -7, -8, and -9 ↑ p-Chk2 ↓ Bcl-xL ↑ DR5 |
↑ Fas ↑ Cell cycle arrest at the G0/G1 phase ↓ CDK4 ↓ Cyclin D1 ↓ p-Rb ↓ Rb ↑ p27 |
[50] |
Legend: ↑, increase; ↓, decrease.